What does ROMAPHARM do?

ROMAPHARM is a pharmacy in Koksijde. Public Limited, started on 22 December 1995, 3 establishments.

What is the address of ROMAPHARM?

The registered office of ROMAPHARM is located at Koninklijke Baan(Kok) 102, 8670 Koksijde.

Is ROMAPHARM still active?

Yes. According to the CBE (30 October 2026) ROMAPHARM is active, legal situation “Normale toestand”, started on 22 December 1995.

Is ROMAPHARM registered on Peppol?

Yes, ROMAPHARM is registered on the Peppol network with ID 0208:0456909689.

What is the enterprise number of ROMAPHARM?

The enterprise number of ROMAPHARM is BE0456909689.

When was ROMAPHARM founded?

ROMAPHARM was founded on 22 December 1995.

Who are the directors of ROMAPHARM?

According to the 2025 annual accounts, the directors of ROMAPHARM are: Marceau DECRU, DEMARAX BV BV, O.P.S. BV.

Is ROMAPHARM a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 22 December 1995; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account; 3 establishments in the CBE.

How much profit did ROMAPHARM make in 2025?

ROMAPHARM posted a profit after taxes of € 140,883 in financial year 2025.

What is the revenue of ROMAPHARM?

As a small company, ROMAPHARM is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 605,275.

How much does an employee at ROMAPHARM earn?

The average wage cost per full-time employee at ROMAPHARM was € 50,700 in 2025: staff costs of € 283,821 for 5.6 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does ROMAPHARM have?

According to the 2025 annual accounts, ROMAPHARM has 5.6 full-time equivalents (FTE).

ROMAPHARM (Public Limited) - Koksijde - BE0456909689

Dossier ROMAPHARM, printed on 30 October 2026 from databakkes.be/en/0456909689/romapharm. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

ROMAPHARM from Koksijde, company number BE0456909689, closed financial year 2025 with a result of € 140,883 after tax. For that financial year ROMAPHARM recorded a gross margin of € 605,275 and equity of € 2.3 million. Compared with financial year 2024, the result moved from € 194,092 to € 140,883. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 10, 2026.

What it is worth Growing

€ 2.3 million

▲ 7% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 140,883

▼ 27% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 344,630

▲ 144% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 2.1 million.

People and assets in 2025

Full-time equivalents

5.6

▲ 0.3 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 283,821

▼ 1% vs 2024

€ 50,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 6,696

▼ 47% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 358,819

▼ 11% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 53,631

▼ 20% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 754,859 Gross margin 2022: € 754,859 First fiscal year in the series	€ 736,402 Gross margin 2023: € 736,402 ▼ 2% vs 2022 (€ 754,859) Unfavourable step	€ 675,398 Gross margin 2024: € 675,398 ▼ 8% vs 2023 (€ 736,402) Unfavourable step	€ 605,275 Gross margin 2025: € 605,275 ▼ 10% vs 2024 (€ 675,398) Unfavourable step	▼ 10%
Profit after taxes	€ 199,921 Profit after taxes 2022: € 199,921 First fiscal year in the series	€ 257,112 Profit after taxes 2023: € 257,112 ▲ 29% vs 2022 (€ 199,921) Favourable step	€ 194,092 Profit after taxes 2024: € 194,092 ▼ 25% vs 2023 (€ 257,112) Unfavourable step	€ 140,883 Profit after taxes 2025: € 140,883 ▼ 27% vs 2024 (€ 194,092) Unfavourable step	▼ 27%
Equity	€ 1,691,508 Equity 2022: € 1,691,508 First fiscal year in the series	€ 1,948,620 Equity 2023: € 1,948,620 ▲ 15% vs 2022 (€ 1,691,508) Favourable step	€ 2,142,712 Equity 2024: € 2,142,712 ▲ 10% vs 2023 (€ 1,948,620) Favourable step	€ 2,283,595 Equity 2025: € 2,283,595 ▲ 7% vs 2024 (€ 2,142,712) Favourable step	▲ 7%
Total debts	€ 869,723 Total debts 2022: € 869,723 First fiscal year in the series	€ 671,160 Total debts 2023: € 671,160 ▼ 23% vs 2022 (€ 869,723) Favourable step	€ 730,050 Total debts 2024: € 730,050 ▲ 9% vs 2023 (€ 671,160) Unfavourable step	€ 682,312 Total debts 2025: € 682,312 ▼ 7% vs 2024 (€ 730,050) Favourable step	▼ 7%
Cash	€ 127,855 Cash 2022: € 127,855 First fiscal year in the series	€ 151,347 Cash 2023: € 151,347 ▲ 18% vs 2022 (€ 127,855) Favourable step	€ 140,972 Cash 2024: € 140,972 ▼ 7% vs 2023 (€ 151,347) Unfavourable step	€ 344,630 Cash 2025: € 344,630 ▲ 144% vs 2024 (€ 140,972) Favourable step	▲ 144%
Land & buildings	€ 588,802 Land & buildings 2022: € 588,802 First fiscal year in the series	€ 483,478 Land & buildings 2023: € 483,478 ▼ 18% vs 2022 (€ 588,802) Unchanged	€ 378,155 Land & buildings 2024: € 378,155 ▼ 22% vs 2023 (€ 483,478) Unchanged	€ 275,457 Land & buildings 2025: € 275,457 ▼ 27% vs 2024 (€ 378,155) Unchanged	▼ 27%
Retained profit	€ 1,519,508 Retained profit 2022: € 1,519,508 First fiscal year in the series	€ 1,776,620 Retained profit 2023: € 1,776,620 ▲ 17% vs 2022 (€ 1,519,508) Favourable step	€ 1,970,712 Retained profit 2024: € 1,970,712 ▲ 11% vs 2023 (€ 1,776,620) Favourable step	€ 2,111,595 Retained profit 2025: € 2,111,595 ▲ 7% vs 2024 (€ 1,970,712) Favourable step	▲ 7%
Bank debt	€ 8,750 Bank debt 2022: € 8,750 First fiscal year in the series	€ 0 Bank debt 2023: € 0 ▼ 100% vs 2022 (€ 8,750) Favourable step	€ 0 Bank debt 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Bank debt 2025: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 2,566,075 Balance sheet total 2022: € 2,566,075 First fiscal year in the series	€ 2,623,010 Balance sheet total 2023: € 2,623,010 ▲ 2% vs 2022 (€ 2,566,075) Unchanged	€ 2,874,377 Balance sheet total 2024: € 2,874,377 ▲ 10% vs 2023 (€ 2,623,010) Unchanged	€ 2,965,907 Balance sheet total 2025: € 2,965,907 ▲ 3% vs 2024 (€ 2,874,377) Unchanged	▲ 3%
Employees (FTE)	7.3 Employees (FTE) 2022: 7.3 First fiscal year in the series	7.3 Employees (FTE) 2023: 7.3 Unchanged (7.3) Unchanged	5.3 Employees (FTE) 2024: 5.3 ▼ 2 vs 2023 (7.3) Unchanged	5.6 Employees (FTE) 2025: 5.6 ▲ 0.3 vs 2024 (5.3) Unchanged	▲ 0.3

Key figures of ROMAPHARM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to ROMAPHARM?

What happened at ROMAPHARM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 10, 2026 New annual accounts for financial year 2025: profit of € 140,883 (▼ 27% vs 2024). Source: NBB ↗
May 13, 2002 New establishment in Koksijde. KBO
Feb 12, 1996 New establishment in Koksijde. KBO
Feb 12, 1996 New establishment in Koksijde. KBO
Dec 22, 1995 Start of the company according to the CBE. KBO

In short

From € 199,921 profit in 2022 to € 140,883 profit in 2025.

Paid € 268,358 in corporate taxes since 2022.

Best year ever: 2023, with € 257,112 profit.

On average € 108,100 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Marceau DECRU DEMARAX BV BV O.P.S. BV

Apotheek Omnia

ALMAPHARMA

ROMAPHARM

OLIVINI

Behind ROMAPHARM are Marceau DECRU, DEMARAX BV BV and O.P.S. BV. The same people are also behind Apotheek Omnia. Marceau DECRU is also behind ALMAPHARMA, ODEPHARMA, APOTHEEK SINT-IDESBALD and DEMARAX. O.P.S. BV is also behind OLIVINI.

Directors

According to the 2025 annual accounts

Marceau DECRU

Director

Also active at: Apotheek Omnia, ALMAPHARMA, ODEPHARMA, APOTHEEK SINT-IDESBALD, DEMARAX

DEMARAX BV BV

Director · represented by Pascale HOUVENAGHEL

Also active at: Apotheek Omnia

O.P.S. BV

Managing director · represented by Geert DECRU

Also active at: Apotheek Omnia, OLIVINI

Establishments

Establishment units

Physical locations of this company

Registered office

Koninklijke Baan(Kok) 102

8670 Koksijde

2.074.897.405

Koninklijke Baan(Kok) 100

8670 Koksijde

Active since 12 February 1996

2.074.897.603

Zeelaan(Kok) 60-62

8670 Koksijde

Active since 13 May 2002

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

Vereniging van Mede-eigenaars Residentie Talassa te Koksijde, Koninklijke Baan 102

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0456.909.689

VAT number

BE 0456.909.689

Registered office

Koninklijke Baan(Kok) 102, 8670 Koksijde

Names & denominations

ROMAPHARM

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

22 December 1995

Peppol

Active · Active since 24 Sept 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

Verhuur en exploitatie van eigen of geleased residentieel onroerend goed, exclusief sociale woningen

View on CBE Public ↗ Annual accounts (NBB) ↗

ROMAPHARM

Financials

What happened to ROMAPHARM?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions